Develops first‑in‑class small‑molecule therapeutics that precisely target pathogenic gut‑lumen pathways identified by a proprietary microbiome and AI discovery platform to treat chronic conditions such as ulcerative colitis, autism spectrum disorder, and Parkinson’s.